Article thumbnail

Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection

By David P. Holland, Gillian D. Sanders, Carol D. Hamilton and Jason E. Stout
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3138781
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1997). A costeffectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.
  2. (2006). An official ATS statement: hepatotoxicity of antituberculosis therapy.
  3. (2000). Causes and costs of hospitalization of tuberculosis patients in the United States.
  4. (1999). Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default.
  5. (2009). Costs and costeffectiveness of four treatment regimens for latent tuberculosis infection.
  6. (2010). Disease Control and Prevention
  7. (1982). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.
  8. (2006). Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
  9. (1975). Frost revisited: the modern epidemiology of tuberculosis.
  10. (2008). Health State Utilities in Latent and Active Tuberculosis.
  11. (1995). Health-care expenditures for tuberculosis in the United States.
  12. (1962). Isoniazid prophylaxis in an undeveloped area.
  13. (1965). Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report.
  14. (1998). Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function.
  15. (1997). Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a riskbenefit and cost-effectiveness analysis.
  16. (2011). North Carolina Tuberculosis Control Program pharmacy data.
  17. (2004). Priorities for the treatment of latent tuberculosis infection in the United States.
  18. (2010). Revisiting rates of reactivation tuberculosis: a population-based approach.
  19. (2000). Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIVinfected persons: an international randomized trial.
  20. (2002). Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
  21. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model.
  22. (2004). Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
  23. (2009). Shortcourse therapy with daily rifapentine in a murine model of latent tuberculosis infection.
  24. (2010). The PREVENT TB Study (TB Trials Consortium Study 26): 3 months of once-weekly rifapentine+INH vs. 9 months of daily INH for treatment of latent TB infection: First report of results of a multi-center, randomized clinical trial.;
  25. (1965). The use of isoniazid among household contacts of open cases of pulmonary tuberculosis.
  26. (2004). Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
  27. (2000). Tuberculosis in the homeless. A prospective study.
  28. (2003). Use of isoniazid for latent tuberculosis infection in a public health clinic.
  29. (2006). Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.